Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Newspaper Publication
News Paper Advertisement regarding to Financial Results for the quarter and nine months ended 31st December 202306-02-2024
06-02-2024
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of the earnings conference call for the quarter and nine months ended December 31, 202306-02-2024
Suven Pharma tanks 10% on poor Q3 show, sharp margin erosion
Suven Pharma reported a sharp decline in its net profit, revenue and profitability in Q3.06-02-2024
Suven Pharmaceuticals Results Earnings Call for Q3FY24
Conference Call with Suven Pharmaceuticals Management and Analysts on Q3FY24 Performance and Outlook. Listen to the full earnings transcript.05-02-2024
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation05-02-2024
Suven Pharmaceuticals Ltd - 543064 - Outcome Of The Board Meeting
unaudited standalone and consolidated financial results for quarter and nine months ended December 31, 2023 , Limited Review Reports, Press Release and Investors Presentation.05-02-2024
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to above subject, please find enclosed herewith an invitation for conducting the conference call for investors on Monday, February 05, 2024 at 06:30 P.M IST to discuss the Un-audited Financial Results for the Q3 & 9M FY24, to be declared on February 05, 2024.30-01-2024
Suven Pharmaceuticals Ltd - 543064 - Board Meeting Intimation for Intimation Of Board Meeting Of The Company To Be Held On Monday, The 05Th February, 2024 - Reg
Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2024 ,inter alia, to consider and approve With reference to above subject, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that a Meeting of the Board of Directors of the Company will be held on Monday, the 05th February, 2024 at 04:00 p.m. IST at the Corporate Office, 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad, Telangana - 500081 of the Company, to consider, inter alia, and To consider and approve the Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the third quarter and nine months ended December 31, 2023 and other matters. With reference to above subject, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that a Meeting of the Board of Directors of the Company will be held on Monday, the 05th February, 2024 at 04:00 p.m. IST at the Corporate Office, 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad, Telangana - 500081 of the Company, to consider, inter alia, and To consider and approve the Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the third quarter and nine months ended December 31, 2023 and other matters.29-01-2024
Suven Pharmaceuticals Ltd - 543064 - Board Meeting Intimation for Intimation Of Board Meeting Of The Company To Be Held On Monday, The 05Th February, 2024 - Reg
Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2024 ,inter alia, to consider and approve With reference to above subject, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that a Meeting of the Board of Directors of the Company will be held on Monday, the 05th February, 2024 at 04:00 p.m. IST at the Corporate Office, 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad, Telangana - 500081 of the Company, to consider, inter alia, and To consider and approve the Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the third quarter and nine months ended December 31, 2023 and other matters.29-01-2024
Suven Pharmaceuticals Ltd - 543064 - Disclosure Pursuant To Regulation 31A(8)(D) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015- Reclassification Approval
Disclosure pursuant to regulation 31A(8)(d) of SEBI LODR - Reclassification Approval13-01-2024